ISRCTN88164211 https://doi.org/10.1186/ISRCTN88164211

Pathophysiology of Dupuytren's Contracture

Submission date	Recruitment status	[ ] Prospectively registered
11/08/2010	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
11/08/2010	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
18/04/2017	Musculoskeletal Diseases	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Liaquat Suleman-Verjee

Contact details
Imperial College London
Kennedy Institute of Rheumatology Division
65 Aspenlea Road
London
United Kingdom
W6 8LH

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
6585

Study information

Scientific Title

Pathophysiology of Dupuytren's Contracture

Study objectives
Dupuytren's disease is a common inheritable disorder, mainly affecting the hand. The digits develop progressive flexion contractures and hand function is significantly impaired. The current mainstay of treatment is surgical excision of the affected tissues but recurrence following excision is seen in approximately 40% of patients. Replacing the palmar skin with grafts obtained from a non-palmar site on the body virtually abolishes recurrence. Based on this well-established surgical observation, we have developed a novel in vitro model that replicates these interactions between skin cells and the contractile cells responsible for Dupuytren's disease. We have also identified a molecule (tenascin-C) that may control the signalling between these cell types.

Ethics approval required
Old ethics approval format

Ethics approval(s)
MREC approved, ref: 06/Q0403/95

Study design
Multicentre non-randomised interventional treatment trial

Primary study design
Interventional

Secondary study design
Non randomised study

Study setting(s)
GP practice

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied
Topic: Generic Health Relevance and Cross Cutting Themes; Subtopic: Generic Health Relevance (all Subtopics); Disease: Surgery

Interventions
Elucidate the exact role of tenascin-C in Dupuytren's disease

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Develop candidate therapeutic target to provide non-surgical intervention to modulate the disease

Secondary outcome measures
Not provided at time of registration

Overall study start date
02/11/2006

Completion date
31/07/2011

Eligibility

Key inclusion criteria
Not provided at time of registration

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Planned sample size: 90

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
02/11/2006

Date of final enrolment
31/07/2011

Locations

Countries of recruitment
England

United Kingdom

Study participating centre

Imperial College London
London
United Kingdom
W6 8LH

Sponsor information

Organisation
Royal College of Surgeons of England (UK)

Sponsor details
35-43 Lincoln's Inn Fields
London
England
United Kingdom
WC2A 3PE

Sponsor type
University/education

Website
http://www.rcseng.ac.uk/

ROR
https://ror.org/02qrg5a24

Funder(s)

Funder type
Charity

Funder Name
Healing Foundation

Alternative Name(s)

Funding Body Type
Private sector organisation

Funding Body Subtype
Other non-profit organizations

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration